(Q38731925)

English

Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity

scientific article published on 10 November 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1 reference

based on heuristic

inferred from title

author name string

Zhiqiang Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Yunmin Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Jiehan Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Qijia Tan

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Caijun Xie

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Cong Li

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Wengang Zhan

7

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Mei Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

10 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

78

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1289-1296

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

https://scigraph.springernature.com/pub.10.1007/s00280-016-3188-2

0 references

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Malignant astrocytic glioma: genetics, biology, and paths to treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Brain cancer in 2012: Molecular characterization leads the way.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Role for Class I histone deacetylases in multidrug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Histone deacetylase inhibitors and cell death

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

HDAC expression and clinical prognosis in human malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Involvement of activating ERK1/2 through G protein coupled receptor 30 and estrogen receptor α/β in low doses of bisphenol A promoting growth of Sertoli TM4 cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3188-2

21 January 2018

Identifiers

10.1007/S00280-016-3188-2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38731925&oldid=1781330029"